Postoperative adjuvant TACE combined with lenvatinib and immune checkpoint inhibitors for hepatocellular carcinoma with high recurrence risks: a multicenter retrospective study

Abstract Background and aims The role of adjuvant therapy for hepatocellular carcinoma (HCC) patients with high recurrence risks after curative resection remains controversial. This study aimed to assess the efficacy and safety of postoperative adjuvant transarterial chemoembolization (TACE) combine...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ziyue Huang, Taifeng Zhu, Xiaokun Chen, Mingjian Piao, Yang Tan, Chengjie Li, Kai Liu, Shanshan Wang, Lei Zhang, Shunda Du, Chengpei Zhu, Kang Zhou, Xiaobo Yang, Daobing Zeng, Haitao Zhao
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2026-01-01
Series:	BMC Cancer
Assuntos:	Hepatocellular carcinoma Adjuvant therapy Transarterial chemoembolization Lenvatinib Immunotherapy Recurrence-free survival
Acceso en liña:	https://doi.org/10.1186/s12885-026-15586-2
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!